Indian Patent Board Orders More Data From Novartis In Glivec Appeal
This article was originally published in PharmAsia News
Novartis, the Swiss drug maker, has been instructed to provide more information if it expects to win its appeal of a ruling against a patent for its Glivec (imatinib) blood-cancer drug. The Intellectual Property Appellate Board told Novartis to submit documents supporting its claim that a newer version of the drug enhanced its efficacy. Novartis is appealing a previous ruling rejecting its claim against generics proposed by Cipla, Natco Pharma and Ranbaxy Laboratories, in addition to the Cancer Patients' Aid Association. (Click here for more
You may also be interested in...
MUMBAI - Swiss-headquartered Novartis announced a tender offer to buy an additional stake of up to 39 percent in its majority-owned Indian subsidiary Novartis India. The Swiss drug maker, which markets popular pain killer Voveran (diclofenac) in India among several other products, would raise its stake in the subsidiary to nearly 90 percent if the open offer for the shares passes successfully
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The International Medical Device Regulators Forum, perhaps most notorious for its efforts to standardize audit processes between nations with its Medical Device Single Audit Program, is also focusing on harmonizing device reviews and adverse event codes.